Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1232
- Registration Number
- NCT06742216
- Locations
- 🇨🇳
Nanjing Gulou Medical College Affiliated Hospital, Nanjing, China
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT06742138
A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 288
- Registration Number
- NCT06686576
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06671548
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 654
- Registration Number
- NCT06649214
Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06644495
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 786
- Registration Number
- NCT06633718
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 336
- Registration Number
- NCT06616571
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT06614907
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06500507
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
© Copyright 2024. All Rights Reserved by MedPath